PMID- 11693065
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20061115
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 47 Suppl 1
DP  - 2001 Sep
TI  - [Prognostic significance of cytogenetic changes in patients with acute myeloid 
      leukemia (AML). (Analysis of results in 105 patients treated at the 
      Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000].
PG  - 8-14
AB  - Chromosomal aberrations are one of the most important prognostic factors in 
      patients with acute myeloid leukemia (AML). This work present analysis of 
      conventional cytogenetic results completed by fluorescence in situ hybridization 
      (FISH) obtained from 105 patients in the time of diagnosis of AML. The median age 
      of patients was 51 years (range 19-79 years), with slight predominance of women 
      (female to male ratio 1.2:1). The evaluated group involved all patients with AML 
      diagnosis, treated by intensive induction chemotherapy in the Department of 
      Hematology-oncology, University Hospital, Olomouc during last 4 years with 
      assessable cytogenetic results. Chromosomal changes were found in 63 (60%) 
      patients. The most often affected chromosomes in succession of frequency were 8, 
      17, 7, 5, 11, 15, 16 a 21. Based on found specific and frequent chromosomal 
      changes the patients were divided into 3 prognostic subgroups and the 
      significance of chromosomal aberrations was evaluated. The subgroup of 17 
      patients with good prognosis consisted of a patients with acute promyelocytic 
      leukemia with translocation t(15;17), 4 patients with t(8;21) and 4 patients with 
      inv(16). 14 patients of 17 live in complete remission, median of overall survival 
      (OS) is 63 weeks. The subgroup of intermediate prognosis was formed by 60 
      patients, 42 had normal karyotype and 18 patients had other chromosomal 
      abnormalities. Median OS of this group was 35 weeks. The third subgroup with poor 
      prognosis consisted of 28 patients with changes of chromosomes 3, 5, 7, 11 and 
      complex karyotype. 64.3% of patients received complete remission and median OS 
      was 35 weeks. Statistical evaluation of OS showed significant difference (p = 
      0.002) in subgroup with good prognosis versus subgroup with poor prognosis and in 
      subgroup with good prognosis versus subgroup with intermediate prognosis (p = 
      0.014). Statistical significance of OS in subgroup with intermediate prognosis 
      versus subgroup with poor prognosis was not proved (p = 0.34), but fit appeared 
      in evaluation of both groups in patients under 55 years. It seems that in 
      patients in age 55 and more the age is independent poor prognostic factor and 
      findings of chromosomal aberrations do not significantly influence prognosis.
FAU - Jarosova, M
AU  - Jarosova M
AD  - Hemato-onkologicka klinika FN a LF UP, Olomouc.
FAU - Indrak, K
AU  - Indrak K
FAU - Holzerova, M
AU  - Holzerova M
FAU - Hubacek, J
AU  - Hubacek J
FAU - Faber, E
AU  - Faber E
FAU - Papajik, T
AU  - Papajik T
FAU - Raida, L
AU  - Raida L
FAU - Szotkowski, T
AU  - Szotkowski T
FAU - Knotkova, R
AU  - Knotkova R
FAU - Hlusi, T
AU  - Hlusi T
FAU - Jedlickova, K
AU  - Jedlickova K
FAU - Pikalova, Z
AU  - Pikalova Z
FAU - Sulovska, I
AU  - Sulovska I
LA  - cze
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Prognosticky vyznam cytogenetickych zmen u nemocnych s akutni myeloidni leukemii 
      (AML). (Analyza vysledku 105 nemocnych lecenych v letech 1997-2000 na 
      Hemato-onkologicke klinice FN a LF UP v Olomouci).
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - *Chromosome Aberrations
MH  - Cytogenetic Analysis
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid/drug therapy/*genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Remission Induction
MH  - Survival Rate
EDAT- 2001/11/06 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/06 10:00
PHST- 2001/11/06 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/06 10:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 2001 Sep;47 Suppl 1:8-14.